Chronic hepatitis B in Asia—new insights from the past decade

@article{Chan2011ChronicHB,
  title={Chronic hepatitis B in Asia—new insights from the past decade},
  author={Henry Lik-Yuen Chan and Jidong Jia},
  journal={Journal of Gastroenterology and Hepatology},
  year={2011},
  volume={26}
}
  • H. Chan, J. Jia
  • Published 1 January 2011
  • Medicine
  • Journal of Gastroenterology and Hepatology
Chronic hepatitis B virus (HBV) infection is a major health problem in the Asia‐Pacific region. In the past decade, much progress has been made in the understanding and management of this disease. The introduction of universal vaccination has significantly reduced the incidence of perinatal infection in most Asia‐Pacific countries. As the majority of the adult population have not been immunized at birth, we are still facing a large population of young HBV‐infected patients in the coming two… Expand
The changing epidemiology of liver diseases in the Asia–Pacific region
TLDR
The expanding implementation of HBV vaccination has been effective in reducing the incidence of liver cancer, especially in countries like China, but further effort is required to tackle the rising prevalence of HCV infection, for which a vaccine is not available. Expand
The Management of Chronic Hepatitis B in Asian Americans
TLDR
The two antiviral agents recommended for first-line treatment of chronic hepatitis B (CHB) are entecavir and tenofovir and these recommendations are based on a review of relevant literature and the opinion of a panel of Asian American physicians with expertise in hepatitis B treatment. Expand
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
TLDR
The final clinical practice guidelines and recommendations for the optimal management of chronic HBV infection are presented here, along with the relevant background information. Expand
Infection and Cancer: The Case of Hepatitis B.
  • S. Chan, V. Wong, S. Qin, H. Chan
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
TLDR
This review aims to use HBV as an example to illustrate the potential of tackling infection-related conditions to help improve cancer outcomes and the status of the development of targeted drugs specifically for HBV-related HCC. Expand
Loss of HBsAg and antiviral treatment: from basics to clinical significance
TLDR
Serum HBsAg titer may reflect the level of intrahepatic hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in most patients, and vary with natural phases of chronic HBV infection, genotypes and variants, antiviral therapy, and other related factors, which might help establish new concept of more practical “response-guided treatment (RGT)” rules for antiviral treatment. Expand
An overview of hepatitis B prevalence, prevention, and management in the Pacific Islands and Territories
TLDR
In this review, the available published literature and World Health Organization data for HBV prevalence and related liver disease and liver cancer burden in PICT is outlined, and unmet needs for improving HBV prevention and control in the region are highlighted. Expand
Why do I treat HBeAg‐positive chronic hepatitis B patients with a Nucleoside analogue
  • H. Ma, J. Jia
  • Medicine
  • Liver international : official journal of the International Association for the Study of the Liver
  • 2013
TLDR
Clinical evidence has shown that once HBV DNA is suppressed and long‐term HBeAg seroconversion is achieved, NAs can be stopped, making NAs the preferred choice for the management of CHB in most patients. Expand
Epidemiology of Hepatitis C Virus Infection in Highly Endemic HBV Areas in China
TLDR
Although Wuwei is a highly endemic area for HBV, the anti-HCV positive rate in the general population is low; more than one-third of HCV-infected people were unaware of their infection; this may become an important risk factor for hepatitis C prevalence in thegeneral population. Expand
Concurrent Infection of Hepatitis B Virus Negatively Affects the Clinical Outcome and Prognosis of Patients with Non-Hodgkin’s Lymphoma after Chemotherapy
TLDR
The study demonstrated that the sustained HBV replication in patients with chronic active HBV infection could be a key factor that influences the prognosis of NHL patients after chemotherapy, and thus may provide information for designing rational clinical treatments for NHL patients with differentHBV infection statuses and improve the treatment efficacy and prognosis. Expand
TLR9: an important molecule in the fight against hepatitis B virus
TLDR
Targeting the defects in TLR9 or reactivating the downstream pathways that are normally switched on byTLR9 in response to HBV infection is a new approach to the treatment of long-termHBV infection, however, the pathways and defects seen in patients with long- term HBV need to be thoroughly explored before therapeutics can be applied in the clinical setting. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 104 REFERENCES
Chronic hepatitis B in Asian women of childbearing age
  • N. Leung
  • Medicine
  • Hepatology international
  • 2009
TLDR
Women of childbearing age are key stakeholders in preventing HBV infection and, as such, play a critical role in reducing the vertical and horizontal transmission of HBV. Expand
Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.
TLDR
The epidemiology, natural history, pathogenesis, and management of HIV/HBV co-infection from regions with high chronic hepatitis B prevalence in Africa and Asia are discussed. Expand
Hepatitis B e antigen–negative chronic hepatitis b in Hong Kong
TLDR
It is found that e−CHB may be present in up to 17% of HBeAg‐negative patients seen in a tertiary referral center in Hong Kong, and may be a heterogenous condition and is not invariably associated with the precore HBV mutant. Expand
Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus–infected patients
TLDR
HBeAg-negative HBV carriers with normal ALT levels have a low risk of hepatitis relapse, and the sensitivity, specificity, and positive and negative predictive values of a single ALT test for hepatitis relapse were 64.9, 71.5, 33.3, and 90.3%, respectively. Expand
Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia.
  • Y. Liaw
  • Medicine
  • Journal of hepatology
  • 2009
TLDR
To address these challenges, the ongoing awareness campaigns, active screening programs, educational activities are needed but must be enhanced, and cost-cutting measures and international support are essential to improve the difficult situation in this part of the world. Expand
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
TLDR
More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality. Expand
Progress in the control of hepatitis B infection in the Western Pacific Region.
TLDR
A number of national programmes still lack the ability to reach all children with immunization services, and major issues that need to be addressed are the challenges of delivering a timely birth dose, and for certain countries, the affordability of the vaccine over the short- and long-term. Expand
The global impact of vaccination against hepatitis B: a historical overview.
TLDR
The effective implementation of such programmes of vaccination has resulted in a substantial decrease in disease burden, in the carrier rate and in hepatitis B-related morbidity and mortality. Expand
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update
TLDR
The new guidelines include general management, special indications for liver biopsy in patients with persistently normal alanine aminotransferase, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Expand
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.
TLDR
The data show that progression to cirrhosis in hepatitis B-infected persons is correlated strongly with the level of circulating virus and is independent of hepatitis B e-antigen status and serum alanine transaminase level. Expand
...
1
2
3
4
5
...